People in the News
Roche announced that Paul Bulcke, a member of the company's board of directors since 2011, has decided not to stand for reelection at its general meeting in 2022. The company proposed Jemilah Mahmood as a replacement. Mahmood is currently the special advisor on public health to Malaysia's prime minister and serves as pro-chancellor of Heriot-Watt University of Malaysia. She is also a professor at and executive director of Sunway Centre for Planetary Health.
Bulcke is the chairman and former CEO of Nestlé and has worked at the firm since 1979. He is also a member of the European Roundtable for Industry and the JP Morgan International Council.
Becton Dickinson has named Joseph Smith as senior VP and CSO. Smith previously served as president and CEO of holding company Digital Health, where he was responsible for the firm's strategy to invest in or acquire digital health and therapeutic technologies. Smith has also held medical, scientific, and technology leadership positions at Johnson & Johnson, Boston Scientific, and the West Health Institute, and has served as academic faculty at Washington University School of Medicine and the school's Department of Biomedical Engineering.
Scott O'Brien has been appointed as chief commercial officer of Specific Diagnostics. Most recently, he was senior VP of global marketing and international sales at GenMark Diagnostics, which was acquired by Roche Diagnostics earlier this year. Prior to joining GenMark 10 years ago, he held various roles at Illumina, Agilent Technologies, and Stratagene. O'Brien holds a BS in microbiology from the University of Wisconsin-Madison.
SomaLogic has hired Steve Mermelstein as SVP of corporate strategy, development and mergers and acquisitions. He was previously VP of strategy and corporate development at Agilent Technologies. Before that, Mermelstein was managing director at Covington Associates, and he was managing director at Huron Consulting Group.
Specific Diagnostics has appointed Scott O'Brien its chief commercial officer. He has more than 20 years of experience in the molecular and infectious disease diagnostics space, including the last decade at GenMark Diagnostics where he was most recently SVP of global marketing and international sales. He previously was at Illumina, Agilent Technologies, and Stratagene.
Meridian Bioscience announced that Executive VP, Secretary, and CFO Bryan Baldasare will retire, effective Dec. 31. The company is currently looking for a new CFO, and Julie Smith has been appointed SVP controller, effective Dec. 6, and principal accounting officer, effective Jan. 1.
Baldasare joined Meridian in 2000 and has served as CFO since 2019. Before becoming CFO, he was the company's chief accounting officer and corporate controller and treasurer. Prior to working at Meridian, he was a senior audit manager at accounting firm Arthur Andersen.
Bionano Genomics has appointed Keith Gligorich as VP of operations for Bionano Laboratories.
Gligorich comes to Bionano from Guardant Health, where he built a CLIA-certified, CAP-accredited lab for blood-based early cancer detection testing. He has also held leadership roles at ARUP Laboratories, Navican Genomics, and Cradle Genomics.
He holds a doctorate in organic chemistry from the University of Utah.
Inflammatix has appointed Kian Beyzavi as an independent member of its board of directors. Beyzavi started her career at management consulting firm McKinsey and has more than 25 years of experience as a venture investor, entrepreneur, consultant, and general manager at Rho Ventures, Cubit Software, Medtronic, Abbott Diabetes Care, and Novartis Diagnostics.
For the past 10 years, she led a specialized consulting firm advising Fortune 500 companies, startups, and others about strategy, product development, business model innovation, commercialization, and monetization of opportunities across life sciences. Beyzavi is a venture partner at multistage investment firm Cota Capital.
Immunovia announced that Patrik Dahlen intends to step down from his position as company president and CEO for personal reasons in 2022, and the search for a new CEO will start immediately. Dahlen will continue with the Lund, Sweden-based company for six months to ensure an orderly transition.
SphingoTec has appointed Jörg Menten its chief commercial officer. He spent 13 years at Boehringer Mannheim including in roles with the firm's point-of-care and lab diagnostics operations, and was CFO of the Boheringer Mannheim Group. He also was president international for Kinetic Concepts, a developer of medical technologies for wounds and wound healing. He later was CEO of Vanguard, a European hospital services firm, and he was president international of CeloNova, a developer of medical devices for treating cardiovascular diseases, prior to its acquisition by Boston Scientific in 2015.